rapamycin

Business news, market intelligence, and global industry analysis.

The Latest

Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue

Sumitomo Forestry expands U.S. housing footprint with $4.5bn Tri Pointe Homes acquisition

Applied Optoelectronics Inc. Texas expansion marks next phase in optical components reshoring push

What Patrick Dumont’s rise to CEO reveals about Las Vegas Sands Corp.’s post-founder strategy

Quoin Pharmaceuticals (NASDAQ: QNRX) spikes over 50% after rapamycin breakthrough in rare disease program

Quoin Pharmaceuticals (NASDAQ: QNRX) stock surged over 50% after achieving key rapamycin delivery targets. Find out how this positions its rare disease pipeline.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 11, 2025